{"entity":{"id":"nct06422936","kind":"trial","name":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)","aka":[],"tldr":"A phase 2 trial of BO-112 in basal cell carcinoma, run by Highlight Therapeutics, active and no longer recruiting.","summary":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) is a phase 2 interventional study registered as NCT06422936 by Highlight Therapeutics, with 60 participants enrolled, started 2024-05-27 and due to reach its primary completion in 2026-06. Interventions recorded: BO-112.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06422936","url":"https://clinicaltrials.gov/study/NCT06422936"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["basal-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06422936","phase":"2","setting":"SPOTLIGHT 204: A Multicenter, Phase 2b, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High Risk Basal Cell Carcinoma","sponsor":"Highlight Therapeutics","enrolled":60,"outcomes":[]},"route":"/trials/nct06422936/","neighbours":{"cancer":[{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/"}]}}